Anti-CD19 & CD28 Bispecific Antibody (RG-6333) from ProteoGenix; catalogue ARO-A22700; research use only.
Know who made it. See the evidence. Buy through one marketplace.
As the field of biotechnology continues to advance, the need for highly targeted and effective treatments becomes increasingly important. That’s where Anti-CD19 & CD28 Bispecific Antibody (RG-6333) comes in. This cutting-edge biotech product is revolutionizing the way we approach disease treatment, offering a powerful and precise solution for a range of conditions.
Anti-CD19 & CD28 Bispecific Antibody (RG-6333) is a novel antibody designed to target two specific proteins, CD19 and CD28, simultaneously. This unique mechanism of action allows for a dual attack on disease cells, enhancing the effectiveness of treatment. By targeting CD19, an antigen found on the surface of B cells, and CD28, a co-stimulatory receptor on T cells, this antibody is able to activate and mobilize the immune system to fight against disease.
This innovative antibody has shown great potential in treating a variety of diseases, including B-cell malignancies, autoimmune disorders, and solid tumors. In particular, it has shown promising results in the treatment of B-cell lymphomas, leukemias, and multiple myeloma. Additionally, it has the potential to be used in combination with other therapies, further enhancing its efficacy.
Anti-CD19 & CD28 Bispecific Antibody (RG-6333) has been extensively studied in pre-clinical and clinical trials, with impressive results. In a phase I clinical trial for relapsed/refractory B-cell lymphoma, it demonstrated a 50% overall response rate and a 33% complete response rate. In another trial for multiple myeloma, it showed a 100% response rate in patients who had previously failed multiple treatments. These promising results highlight the potential of this antibody as a game-changing treatment option.
In addition, ongoing research is exploring the use of this antibody in combination with other therapies, such as CAR-T cell therapy, to further enhance its effectiveness. This opens up new possibilities for treating diseases that were previously difficult to target.
In conclusion, Anti-CD19 & CD28 Bispecific Antibody (RG-6333) is a groundbreaking biotech product with a unique mechanism of action and promising results in a range of diseases. Its potential to be used in combination with other therapies makes it a versatile and powerful treatment option. Stay ahead of the game and incorporate this innovative antibody into your research today.
ProteoGenix catalogue number ARO-A22700. For research use only.
Target: B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19, T-cell-specific surface glycoprotein CD28, TP44, CD28, CD28; Clonality: Monoclonal Antibody; Applications: Functional assay, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | Functional assay |
|---|---|---|---|---|---|---|---|---|---|
| B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19, T-cell-specific surface glycoprotein CD28, TP44, CD28, CD28 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
